Hepatology

An investigational GLP-1 dual agonist, DD01, reduced liver fat in adults with MASLD or MASH in a phase 2 trial.

Living donor liver transplant rates recovered after 2009, but disparities persisted, with Black patients continuing to experience lower access.

Gallbladder cancer diagnosis may be improved using circulating cell-free DNA, with a pilot study identifying fragmentomics features that distinguished cancer from non-cancer cases.

Patients who initiated everolimus after liver transplantation had a lower incidence of new cancers in a nationwide French analysis using emulated clinical trials.

A transcriptome-based machine learning model accurately predicted hepatocellular carcinoma recurrence and identified COL2A1 as a potential protective factor, supporting further investigation before clinical implementation.

Microplastics were detected in tumour samples and PVC microplastics may influence radiotherapy response through changes in tumour immunity.

A proposed hepatitis C elimination initiative in the US was projected to prevent thousands of deaths, reduce HCV cases and save billions in healthcare spending.

Combining laboratory and pharmacy data provided the most rigorous measure of hepatitis C care outcomes, although follow-up RNA testing remained incomplete.